Nissan Chemical (4021) · FactRestated
Change in Reporting Segment Classification and Renaming of the Pharmaceuticals Business as the Healthcare Business
First written in FY2023-Q1. 1 of 2 entries say "Restated". Latest entry: FY2023-Q2.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Reorganization of 5 pharmaceutical, pharmacy and other reporting segments as part of the transition to a health-creation business groupA theme 2 companies write about · 0 as a headwind · 0 as a tailwind
0 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2023-Q2RestatedAnnual report
「In connection with an organizational change effective 1 April 2022, we renamed the Pharmaceuticals Business as the Healthcare Business and changed the reportable segment to which certain departments belonged, beginning with the first quarter of the current fiscal year.」
The renaming of the business as the Healthcare Business and the change in segment classification resulting from the organizational change effective 1 April 2022 have continued to be applied, and comparative information has been prepared using the revised classification. - FY2023-Q1First statedAnnual report
「In connection with an organizational change effective 1 April 2022, we renamed the Pharmaceuticals Business as the Healthcare Business and changed the reportable segment to which certain departments belonged, beginning with the first quarter of the current fiscal year.」
In connection with the organizational change, the reportable segment name was changed from the Pharmaceuticals Business to the Healthcare Business, and the reportable segment classification of certain departments was also changed.